Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 53 articles: HTML format

Single Articles

August 2025
1. RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al
   Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
   Clin Cancer Res. 2025;31:3599.
   PubMed    
   
   
   
2. KNISELY A, Dai Y, Barlow GL, Lee S, et al
   Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities.
   Clin Cancer Res. 2025 Aug 1. doi: 10.1158/1078-0432.CCR-25-0512.
   PubMed     Abstract available
   
   
   July 2025
3. RAI L, Ravaggi A, Bignotti E, Hollis RL, et al
   Oxford Classic-defined EMT risk stratification of High Grade Serous Ovarian cancer for guiding treatment decisions.
   Clin Cancer Res. 2025 Jul 24. doi: 10.1158/1078-0432.CCR-24-4250.
   PubMed     Abstract available
   
   
   
4. NGOI NYL, Choi CH, Zhu J, Lim D, et al
   Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial.
   Clin Cancer Res. 2025 Jul 24. doi: 10.1158/1078-0432.CCR-25-0201.
   PubMed     Abstract available
   
   
   
5. MARCHENKO S, Goernitz N, Zoern WA, Joosten M, et al
   Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-Grade Serous Tubo-ovarian Cancer.
   Clin Cancer Res. 2025 Jul 15. doi: 10.1158/1078-0432.CCR-24-2794.
   PubMed     Abstract available
   
   
   May 2025
6. CONCIN N, Braicu I, Combe P, Berger R, et al
   GANNET53 Part II: A European Phase I/II Trial of the HSP90 inhibitor Ganetespib in high-grade Platinum-Resistant Ovarian Cancer - A Study of the GANNET53 consortium.
   Clin Cancer Res. 2025 May 28. doi: 10.1158/1078-0432.CCR-24-3705.
   PubMed     Abstract available
   
   
   
7. COLLET L, Ardin M, Venet D, Berthet J, et al
   Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial.
   Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2712.
   PubMed     Abstract available
   
   
   
8. CHUI MH, Kang EY, Kahn RM, Chiang S, et al
   Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-Grade Serous Tumors with Histologic Transformation.
   Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-3168.
   PubMed     Abstract available
   
   
   April 2025
9. KAAKS R, Cooley V, Mukama T, Teras LR, et al
   A Prospective Study Consortium for the Discovery and Validation of Early Detection Markers for Ovarian Cancer ("PREDICT") - Baseline findings for CA125.
   Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1845.
   PubMed     Abstract available
   
   
   
10. LEE JM, Miller A, Rose PG, AlHilli M, et al
    Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3877.
    PubMed     Abstract available
    
    
    March 2025
11. COSCIA F, Nielsen AB, Weigert M, Watters K, et al
    A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer.
    Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-1763.
    PubMed     Abstract available
    
    
    
12. BANERJEE S, Ghisoni E, Wolfer A, Ottevanger PB, et al
    Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study.
    Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3368.
    PubMed     Abstract available
    
    
    
13. PARK J, Joung JG, Lim MC, Lee J, et al
    Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.
    Clin Cancer Res. 2025 Mar 5. doi: 10.1158/1078-0432.CCR-24-3753.
    PubMed     Abstract available
    
    
    January 2025
14. ALQAISI HA, Cohn DE, Chern JY, Duska LR, et al
    Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI trial).
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3128.
    PubMed     Abstract available
    
    
    December 2024
15. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    PubMed     Abstract available
    
    
    October 2024
16. BRAVO MELGAR J, Laoui D
    Chemotherapy Sparks Tertiary Lymphoid Structures in Metastatic Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-2738.
    PubMed     Abstract available
    
    
    
17. CHAE YK, Othus M, Patel SP, Wilkinson KJ, et al
    SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-0606.
    PubMed     Abstract available
    
    
    September 2024
18. JEON SH, You G, Park J, Chung Y, et al
    Anti-4-1BBxPDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Clin Cancer Res. 2024;30:4155-4166.
    PubMed     Abstract available
    
    
    August 2024
19. LANICKOVA T, Hensler M, Kasikova L, Vosahlikova S, et al
    Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
    Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1594.
    PubMed     Abstract available
    
    
    July 2024
20. RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al
    Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice.
    Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-1225.
    PubMed     Abstract available
    
    
    June 2024
21. SANER FAM, Takahashi K, Budden T, Pandey A, et al
    Concurrent RB1 Loss and BRCA-Deficiency Predicts Enhanced Immunological Response and Long-Term Survival in Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-3552.
    PubMed     Abstract available
    
    
    May 2024
22. CORBAUX P, Freyer G, Glehen O, You B, et al
    Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
    Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-24-0507.
    PubMed     Abstract available
    
    
    April 2024
23. LORENTZEN GM, Laniewski P, Cui H, Mahnert ND, et al
    Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification.
    Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2934.
    PubMed     Abstract available
    
    
    
24. NIEF CA, Hammer PM, Wang A, Charu V, et al
    Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3158.
    PubMed     Abstract available
    
    
    
25. YANIZ-GALENDE E, Zeng Q, Grau-Bejar JF, Klein C, et al
    Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3836.
    PubMed     Abstract available
    
    
    
26. VENEZIANI AC, Sneha S, Oza AM
    Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
    Clin Cancer Res. 2024;30:1434-1437.
    PubMed     Abstract available
    
    
    
27. GITTO SB, Whicker M, Davies G, Kumar S, et al
    A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
    Clin Cancer Res. 2024;30:1567-1581.
    PubMed     Abstract available
    
    
    January 2024
28. TAN TJ, Sammons S, Im YH, She L, et al
    Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-2513.
    PubMed     Abstract available
    
    
    
29. WANG Y, Situ X, Cardenas H, Siu E, et al
    Preclinical evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.
    Clin Cancer Res. 2024 Jan 17. doi: 10.1158/1078-0432.CCR-23-2368.
    PubMed     Abstract available
    
    
    December 2023
30. TSANG ES, Gallinger S
    Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer.
    Clin Cancer Res. 2023;29:5005-5007.
    PubMed     Abstract available
    
    
    
31. BROWN TJ, Yablonovitch A, Till JE, Yen J, et al
    The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
    Clin Cancer Res. 2023;29:5207-5216.
    PubMed     Abstract available
    
    
    
32. WANG Y, Douville C, Chien YW, Wang BG, et al
    Aneuploidy Landscape in Precursors of Ovarian Cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-0932.
    PubMed     Abstract available
    
    
    November 2023
33. DREW Y, Kim JW, Penson RT, O'Malley DM, et al
    Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2249.
    PubMed     Abstract available
    
    
    
34. SOBERANIS PINA P, Oza AM
    Methodical Manipulation of the TME in Ovarian Cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2365.
    PubMed     Abstract available
    
    
    October 2023
35. BUCKLEY DN, Lewinger JP, Gooden G, Spillman M, et al
    OvaPrint - a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer.
    Clin Cancer Res. 2023 Oct 9. doi: 10.1158/1078-0432.CCR-23-1197.
    PubMed     Abstract available
    
    
    September 2023
36. JAMIESON A, Vermij L, Kramer CJH, Jobsen JJ, et al
    Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas.
    Clin Cancer Res. 2023 Sep 29. doi: 10.1158/1078-0432.CCR-23-1397.
    PubMed     Abstract available
    
    
    
37. LEMAN R, Muller E, Legros A, Goardon N, et al
    Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
    Clin Cancer Res. 2023 Sep 26:OF1-OF11. doi: 10.1158/1078-0432.CCR-23-0898.
    PubMed     Abstract available
    
    
    August 2023
38. GRISHAM RN, Vergote I, Banerjee S, Drill E, et al
    Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2023 Aug 15:CCR-23-0621. doi: 10.1158/1078-0432.CCR-23-0621.
    PubMed     Abstract available
    
    
    
39. TAVIRA B, Iscar T, Manso L, Santaballa A, et al
    Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
    Clin Cancer Res. 2023 Aug 1:CCR-23-0771. doi: 10.1158/1078-0432.CCR-23-0771.
    PubMed     Abstract available
    
    
    July 2023
40. DOE-TETTEH SA, Camp SY, Reales D, Crowdis J, et al
    Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach.
    Clin Cancer Res. 2023;29:2445-2455.
    PubMed     Abstract available
    
    
    June 2023
41. GARG V, Oza AM
    Assessment of Homologous Recombination Deficiency in Ovarian Cancer.
    Clin Cancer Res. 2023 Jun 22:CCR-23-0563. doi: 10.1158/1078-0432.CCR-23-0563.
    PubMed     Abstract available
    
    
    
42. HEINZE K, Cairns ES, Thornton S, Harris B, et al
    The prognostic effect of immune cell infiltration depends on molecular subtype in Endometrioid Ovarian Carcinomas.
    Clin Cancer Res. 2023 Jun 20:CCR-22-3815. doi: 10.1158/1078-0432.CCR-22-3815.
    PubMed     Abstract available
    
    
    
43. LHEUREUX S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, et al
    Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression.
    Clin Cancer Res. 2023 Jun 16:CCR-23-0797. doi: 10.1158/1078-0432.CCR-23-0797.
    PubMed     Abstract available
    
    
    May 2023
44. DILAWARI A, Shah M, Ison G, Gittleman H, et al
    FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRalpha-positive, Platinum-Resistant Ovarian Cancer.
    Clin Cancer Res. 2023 May 22:CCR-23-0991. doi: 10.1158/1078-0432.CCR-23-0991.
    PubMed     Abstract available
    
    
    
45. GONZALEZ-OCHOA E, Oza AM
    An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian cancer.
    Clin Cancer Res. 2023 May 16:CCR-23-0652. doi: 10.1158/1078-0432.CCR-23-0652.
    PubMed     Abstract available
    
    
    
46. DORIGO O, Oza AM, Pejovic T, Ghatage P, et al
    Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.
    Clin Cancer Res. 2023 May 1:CCR-22-2595. doi: 10.1158/1078-0432.CCR-22-2595.
    PubMed     Abstract available
    
    
    April 2023
47. COMPADRE AJ, van Biljon LN, Valentine MC, Llop-Guevara A, et al
    RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-3335. doi: 10.1158/1078-0432.CCR-22-3335.
    PubMed     Abstract available
    
    
    
48. WETHINGTON SL, Shah PD, Martin L, Tanyi JL, et al
    Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-2444. doi: 10.1158/1078-0432.CCR-22-2444.
    PubMed     Abstract available
    
    
    
49. BLANC-DURAND F, Tang R, Pommier M, Nashvi M, et al
    Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3328. doi: 10.1158/1078-0432.CCR-22-3328.
    PubMed     Abstract available
    
    
    
50. KIM YN, Shim Y, Seo J, Choi Z, et al
    Investigation of poly ADP-ribose polymerase inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3715. doi: 10.1158/1078-0432.CCR-22-3715.
    PubMed     Abstract available
    
    
    
51. LIU YL, Zamarin D
    Shedding Light on PARP Inhibitor Response through Functional Imaging.
    Clin Cancer Res. 2023;29:1384-1386.
    PubMed     Abstract available
    
    
    March 2023
52. BATALINI F, Mina LA, Mina A
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter.
    Clin Cancer Res. 2023;29:1157.
    PubMed    
    
    
    
53. MARMOUSET V, Morice PM, Pages A, Leary A, et al
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.
    Clin Cancer Res. 2023;29:1158-1159.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.